Clinical and Molecular Phenotyping in IBD

NCT02694588 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

90

Enrollment

OTHER

Sponsor class

Conditions

IBD

Interventions

DRUG: Infliximab
DRUG: Vedolizumab

Sponsor

University Hospital Schleswig-Holstein